Hematological Cancer Archives - Xtalks

Wednesday, August 12, 2026 | 11am EDT: Accelerate Cell Culture Media Development with Automated Cell Analysis

FDA Approves Tregzi: A New Way to Reduce Complications After Blood Cancer Transplants

Redefining Hematologic Malignancy Drug Development: How Molecular Reclassification, MRD, & AI is Reshaping Precision Hematology

Blenrep Combination Wins FDA Nod in Relapsed or Refractory Multiple Myeloma

October 24, 2025

World Blood Cancer Day 2025: New Strides in Treating Leukemia, Lymphoma and Rare Blood Malignancies

Business & Finance News

Ascentage Pharma IPO Comes In Strong with Phase III Candidates for Hematological Cancers

January 28, 2025

Clinical Trial News

Tamibarotene Fails in Phase III Trial for a Subset of Higher-Risk MDS

November 15, 2024

Gene Therapy Skysona Linked to 7 Cases of Blood Cancer

October 15, 2024

After Three Decades in the Making, Geron’s Telomerase Inhibitor Rytelo Gets FDA Nod for Lower-Risk MDS

Life Science Spotlight

Clonal Hematopoiesis and Cancer Genetics: How Are They Linked, How Is Research Evolving?

The Voice of the Hematological Malignancy Patient: Are You Listening?

November 16, 2023

Interview with Dr. Kristin Yarema, President of Cell Therapy at Poseida Therapeutics – Xtalks Life Science Podcast Ep. 129

September 27, 2023

Developing More Affordable Cellular Immunotherapies: Interview with CytoMed Therapeutics — Xtalks Life Science Podcast Ep. 117

Developing a Novel Assay for Circulating Multiple Myeloma Cells Using the CELLSEARCH Platform

November 20, 2020

Celgene and Juno in Talks Over Potential Acquisition

January 18, 2018